Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.74 |
| ▸ | SRC | P12931 | 9/20 | 0.74 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.69 |
| ▸ | CSK | P41240 | 3/20 | 0.69 |
| ▸ | TEK | Q02763 | 3/20 | 0.69 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 5/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 2/20 | 0.53 |
| ▸ | KIF5B | P33176 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5217413 | 0.99 | KDR (0.73) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL5214679 | 0.88 | SRC (0.80) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL5217352 | 0.86 | SRC (0.78) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL3205132 | 0.85 | SRC (1.00) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL5215250 | 0.85 | KDR (0.75) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL5215259 | 0.85 | KDR (0.75) | KDRSRCEPHB4CSKTEK | |
| Hydrochloric Acid SCHEMBL5222294 | 0.85 | KDR (0.67) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL5220271 | 0.83 | SRC (0.66) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL5218186 | 0.83 | SRC (0.92) | KDRSRCEPHB4CSKTEK | |
| SCHEMBL3196191 | 0.82 | SRC (1.00) | KDRSRCEPHB4CSKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |